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Pigment epithelium-derived factor (PEDF) is a secreted glycoprotein and a non-inhibitory member of the serine
protease inhibitor (serpin) family. It is widely expressed in human fetal and adult tissues but its expression decreases
with age and in malignant tissues. The main anti-cancer activities of PEDF derive from its dual effects, either
indirectly on the tumor microenvironment (indirect antitumor action) or directly on the tumor itself (direct
antitumor influence). The indirect antitumor activities of PEDF were uncovered from the early findings that it
stimulates retinoblastoma cell differentiation and that additionally it possesses anti-angiogenic, anti-tumorigenic and
anti-metastatic properties. The mechanisms of its direct antitumor effect, however, have not been fully elucidated. This
review highlights recent progress in our understanding of the multifunctional activities of PEDF and, in particular, its
anti-cancer signaling mechanisms. Additionally, we discuss the possibility of using novel phosphaplatin compounds
that can upregulate PEDF expression as a chemotherapy for cancer treatment.
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Cancer, which remains the second-leading cause of death
in the United States, accounts for nearly one in every four
deaths. The American Cancer Society estimates that
569,490 Americans died of cancer in 2010 (www.cancer.
org/docroot/stt/stt_0.asp), despite the significant advances
in recent years in surgical resection, adjuvant chemother-
apy, and radiotherapy. This situation highlights an urgent
need for novel therapies, such as targeted therapy that fo-
cuses on particular pathways and mechanisms of tumor
growth that are restricted to cancer. Pigment epidermal-
derived factor (PEDF) is one of several cellular molecules
that have been explored for use in targeted therapy.
PEDF (also known as EPC1) is a member of the serpin
(serine protease inhibitors) superfamily of proteins, and
is commonly expressed in normal tissues [1–5], and to a
lesser extent, in tumorous tissues [6, 7]. PEDF exhibits a
broad spectrum of activities, and the most prominent* Correspondence: lbelkace@central.uh.edu; xzhang5@central.uh.edu
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activity and neurotrophic effect [8]. Other activities
include stimulation of inflammation [9], and tumori-
genesis [10, 11]. Investigation of PEDF-knockout mice
confirmed a crucial role for this factor as a regulator
of the angiogenic functions [12]. Additional studies
demonstrated that PEDF is a potent inhibitor of
tumor angiogenesis [13], as this factor not only sup-
presses blood vessel endothelial cell proliferation and
migration, but also enhances cell apoptosis [13, 14].
The anti-tumor effects of PEDF are particularly evi-
dent in tumors where PEDF exerts both an indirect
impact on tumor angiogenesis and a direct effect on
tumor cells. Such anti-tumor effects have been ob-
served in cancers of different tissue origins, including
prostatic [12, 15–17] ovarian [18, 19], and pancreatic
carcinomas [20]; melanomas [21–23]; gliomas [24, 25];
and osteosarcoma [26–29]. Remarkably, PEDF displays
the opposite effect in certain healthy tissues, especially
neural cells. For instance, in cerebellum granule cells,
PEDF protects against both natural and potassium-
induced apoptosis via activation of pro-survival genes
[30]. Moreover, in cultured retinal pericytes, PEDFhis article is distributed under the terms of the Creative Commons Attribution
ons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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whereas in vivo PEDF blocks light-induced apoptotic pro-
cesses in photoreceptor cells [32, 33]. These studies and
others indicate that PEDF plays a cardinal role in the
physiology and pathophysiology of the human body, and
that the mechanisms of action of this factor depend on
whether PEDF targets a blood vessel or a tumor.
In this review, we discuss the anti-tumor activities of
PEDF and focus on its dual role as an inhibitor (e.g.,
angiogenesis) and as an inducer of various vital bio-
logical processes that lead to the therapeutic effect via
different mechanisms of action. Furthermore, we de-
scribe the potential use of a novel class of platinum-
based compounds, the phosphaplatins, which upregulate
PEDF expression, as a new treatment strategy for malig-
nant tumors.
Properties of PEDF and its receptors










TuPEDF is a monomeric 50-kDa glycoprotein [34]
encoded by the SERPINF1 gene, which is localized
on chromosome 17p13. The crystal structure of
PEDF was successfully elucidated in 2001, revealing
that PEDF has a tertiary structure similar to
other members of the Serpin family. This structure
contains three β-sheets and 10 α-helices [35, 36] as
well as a usual reactive centre loop (RCL; residues
373–380) near the C-terminus [37, 38]. PEDF also
exhibits an asymmetrical charge distribution
across the whole protein, as one side of the
protein is heavily basic and the other side is
heavily acidic, leading to a polar 3-D structure.
Some domain sites, such as those for binding to
collagen, heparin, and hyaluronan, were mapped on
the human PEDF using either protein chemistry or
genetic engineering [39–42].
(ii) Amino acid composition and functional domains
of PEDFble 1 PEDF functional domains
nction Peptide sites
ti-angiogenesis 34-mer peptide region (residues 24
llagen binding (anti-angiogenesis) Asp256,Asp258, Asp300 (negatively
and Asp299 are critical to collagen
ll differentiation 44-mer peptide region (residues 58
parin binding Arg145, Lys146 and Arg148
aluronan Lys189, Lys191, Arg194 and Lys197
minin binding 34-mer peptide region (residues 44
osphorylation Ser24, Ser114, Ser227
urotrophy 44-mer peptide region (residues in
mor cell apoptosis 34-mer peptide region (residues 24At least four isoforms of secreted human and
bovine PEDF have been detected [43]. PEDF is
a polypeptide composed of 418 amino acids
[44], most of which form secondary structures
with the exception of the first 35 residues at the
N-terminus (residues 1–35). The anti-angiogenic
properties and neurotrophic activities localize to the
N-terminal region of the polypeptide, whereas the
C-terminal region interacts with the membrane
receptor [45]. The distinct functional domains of
PEDF are summarized in Table 1. The deduced
amino acid sequence contains consensus sequences
for N-linked glycosylation and several predicted sites
for phosphorylation and O-linked glycosylation. The
significance for some of these post-translational
modifications is currently unclear.
(iii) PEDF receptors identification and function
For the last 15 years several research groups
showed that PEDF distinct receptors, present in
the plasma membranes of various cell types, can
elicit different signals [46]. At least two of these
PEDF receptors (PEDF-Rs) have been proposed by
earlier studies. An 80-kDa PEDF receptor (PEDF-
RN) with high affinity to the 44-mer PEDF peptide,
is involved in neurotrophic activity, and a 60-kDa
PEDF receptor (PEDF-RA) with high affinity to the
34-mer PEDF detected in plasma membranes of
retina, retinoblastoma, and central nervous system
[15, 36, 47–49]. The PEDF-RN is a phospholipase
and triglyceride lipase associated with triglyceride
metabolism [36]. It is known in mice as adipose
triglyceride lipase-ATGL, desnutrin, and patatin-
like phospholipase domain containing protein-
PNPLP2, iPLAζ, and in humans as transport
secretion protein-2.2 (TTS-2.2)/independent
phospholipase Aζ [50]. The result of the binding of
PEDF to PNPLA2 stimulating a given molecular
signaling pathway is still elusive. However, it has
been suggested that the localization of PNPLA2–57)
charged), Arg149, Lys166, Lys167 (positively charged). Asp255, Asp257
-I-binding
–101)
form a motif that is critical for hyaluronan binding (Becerra et al. [42])
–77) (Bernard et al. [46])
humans 78–121)
–57)
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system may denote a neurotrophic role of this
receptor upon activation of PEDF. Moreover, upon
PEDF binding, the PEDF-RN can potentially induce
phospholipase A2 liberating fatty acids and
lysophosphatidic acid from phospholipids [50–52],
which could act as second messengers for signal
transduction in neuronal cell development and
survival, or possibly trigger anti-tumorigenic
(e.g. apoptotic role of fatty acids omega-3
docosahexaenoic acid (DHA) in tumour cells
[53]. The PEDF-RA is a receptor for laminin as well
[46]. The laminin receptor (LR)-interacting domain
on PEDF is localized to a 34-aa peptide (aa 44–77);
whereas the PEDF-interacting domain on LR is
located to a 91-aa fragment (aa 120–210). A 25-mer
peptide called P46 (aa 46–70), derived from the 34-
mer peptide of PEDF, is the part that interacts with
LR. The binding of the 25-mer PEDF region to the
LR on endothelial cell triggers apoptosis, whereas
angiogenesis, migration, tumour cell adhesion and
proliferation are blocked. According to Bernard et al.
[46], the binding of PEDF to the LR represents a
novel signaling pathway for anti-angiogenic activities
of PEDF. The investigators also suggest that PEDF
binding to the LR could possibly stimulate multiple
apoptotic pathways independent of the FAS/FASL
death pathway including MAPK, JNK, and p38.
Additionally, a group of extracellular proteins have
been shown to influence angiostatic functions of
PEDF. For example, PEDF binds to collagen I
(Table 1), which might change the integrin–
collagen I interaction, and affect endothelial cell
adhesion and docking [41, 54] with subsequent
negative effect on angiogenesis. Further, PEDF
binding to collagen II [41], collagen III [41] or
glycoaminoglycans [55] probably enable anti-
angiogenic functions of PEDF as well.
Recently, a new ~60-kDa PEDF binding protein
has been purified from membrane extracts of
bovine retina tissues, retinoblastoma cells [47, 48],
and endothelial cells [56]. The protein matches
ectopic F1-ATP synthase β-subunit and is being
considered as another receptor for PEDF. PEDF
interacts and inhibits endothelial and tumor cell
surface F1-ATP synthase [56] and prevents the
formation of ATP from ADP and inorganic
phosphate by the enzyme. Since ATP and ADP
have receptors on cell surfaces, they are likely to
represent mediators of PEDF. A modification in
ATP levels could negatively affect many cell
biological processes including cell viability [56].
Last year two other proteins; PLXDC1 (also called
tumor endothelial marker 7 or TEM7; ~60-kDa)and PLXDC2 (also named TEM7-related or
TEM7R, ~56-kDa) were identified as cell-surface
receptors for PEDF. [2] These two membrane
proteins have a large extracellular domain, a
transmembrane domain, and an intracellular
domain, and share about 50 % homology. Expression
studies have uncovered overlapping between the two
proteins. However distinctive tissue expression
patterns of PLXDC1 [57, 58], and PLXDC2
[59–61] respond to PEDF. [2] Interestingly, each
receptor can play separate roles in different cell
types. For instance, exposing one type of cell
from blood vessels to PEDF would normally kill
them, but cells lacking PLXDC2 (but not those
missing PLXDC1) could survive PEDF treatment.
Cheng et al. [2] discovered that in the absence of
PEDF, both PLXDC1 and PLXDC2 form complexes
containing more than one copy of either receptor,
but as soon as PEDF binds to the receptors, it
caused these complexes to disassemble, leading to
the activation of downstream signaling processes in
the cell.
All together these findings suggest that PEDF-Rs
play a decisive role in cell biological functions.
Thus, the search for new PEDF-Rs and the signaling
pathways they stimulate after the binding of PEDF
must continue. Comprehending PEDF receptors
and their mechanisms will eventually lead to the
development of new drugs that target these receptors
to treat human diseases including cancer.PEDF secretion and function under normal
conditions
PEDF was first purified from conditioned media from
human retinal pigment epithelial (HRPE) cells [62].
Since then, this endogenously produced protein has been
detected in many tissues, including eyes, liver, heart, and
adipose tissue, implying that PEDF has diverse and sig-
nificant biological activities. The reported functional as-
sociation of PEDF with both organogenesis [12, 63, 64],
and homeostatic maintenance of adult tissues/organs
[12, 65–68] supports this notion. The physiological
PEDF serum concentration in healthy people, however,
remains controversial, as reports have demonstrated
values ranging from 4 ng/ml to 15 μg/ml [69–74], de-
pending on the method of measurement [4, 69]. Despite
these inconsistencies, PEDF production clearly decreases
with age and in some diseases, such as nephropathy
[75, 76], suggesting the importance of this factor for
maintaining homeostasis. In the particular case of
cancer, contrary to expectations, a recent study of
prostate cancer showed that although the expression
of PEDF was only detected in few tumor cells by im-
munohistochemistry, PEDF level in the venous blood
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[77]. The investigators speculated that the elevation
of PEDF may represent a protective mechanism
against the tumor, manifested by an anti-tumor effect
in patients with aggressive prostate cancer [78, 79].
They proposed PEDF as a potential biomarker that
would mirror the level of tumor aggressiveness and
allow risk stratification of patients with prostate can-
cer. This example shows that further clarification of
the clinical role of PEDF is essential for a better cor-
relation of PEDF production in cancer patients with
clinical and pathological parameters.
In summary, PEDF is a multifunctional protein and it
possesses neurotrophic, neuroprotective, anti-angiogenic,
and anti-cancer activities [34, 80–82]. In the following sec-
tions, we focus this review on the anti-cancer activities of
PEDF.
Effect of PEDF on tumors
One of the most interesting properties of PEDF is its
anti-cancer effect. As detailed in the subsequent sec-
tions, this pluripotent protein can reduce tumor growthDifferentiation










Fig. 1 Modulation of the expression of PEDF affects tumor growth either (
prevention of cell proliferation, invasion and metastasis in concert with the
the absence of PEDF, (+) refers to the presence of PEDF, (→) means proteieither indirectly through the inhibition of angiogenesis,
or directly via the prevention of cell proliferation, inva-
sion and metastasis in concert with the promotion of
cell apoptosis and/or differentiation (Fig. 1).






A tumor is unable to grow to more than about
1 mm3 without the development of a new blood
supply [83, 84]. Angiogenesis is a process that
involves the growth of new blood vessels from
pre-existing vessels [85]. This multistep process
involves proliferation, migration, basement
membrane degeneration, and new lumen
formation, using the endothelial cells that line
the inner surface of the blood vessels. This
process is tightly regulated by both positive
and negative signals [86, 87]. Among the positive
factors, angiogenic vascular endothelial growth
factor (VEGF) is one of the most highly expressed
marker in tumors [88, 89]. Because of its varied
anti-angiogenic functions, PEDF is consideredIndirect effect on tumors 
lial cells 
sis
Blood  vessels 
Angiogenesis AngiogenesisProliferation
+ -+ 
ectly through the inhibition of angiogenesis, or directly via the
otion of cell apoptosis and/or differentiation. (−) PEDF means
ation, and (—) means protein inhibition
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factors.
PEDF is a selective inhibitor of angiogenesis
and targets only new vessel growth while
sparing the pre-existing vasculature [90, 91].
Dawson et al. were the first to suggest a role for
PEDF in angiogenesis [13]. They found that
PEDF regulated blood vessel growth by creating
a relaxed atmosphere for angiogenesis when
oxygen was reduced (hypoxic conditions) such
as in tumors, and an inhibitory environment
when levels of oxygen were normal or high
[13]. Doll et al. [12] also studied the role of
PEDF in angiogenesis using PEDF knockdown
mice. Their results showed that PEDF-deficient
mice had significantly increased prostate stromal
vasculature along with evident epithelial
hyperplasia, suggesting a major role for PEDF
in vascular/angiogenic functions. A notable
characteristic of PEDF is its strong anti-angiogenic
activity, as compared with other endogenous
inhibitors of neovascularization, including
thrombospondin, angiostatin or endostatin [13].
The exact molecular mechanism by which PEDF
impedes angiogenesis is still not fully understood;
however, PEDF-mediated anti-angiogenesis can
result from enhanced gamma-secretase activity.
This transmembrane cleaves single-pass
transmembrane proteins at residues within
the transmembrane domain, leading to the
cleavage of the VEGF receptor-1 (VEGFR-1)
transmembrane domain [92]. This action
interferes with VEGF signaling, thereby inhibiting
angiogenesis. In addition, as a major antagonist
of VEGF, PEDF effectively blocks VEGF-driven
angiogenesis and vascular permeability by
regulating the proteolysis of VEGF [92]. The
direct binding of PEDF to VEGFR-1 or VEGFR-2
promotes internalization and degradation of
these receptors in VEGF-stimulated endothelial
cells [93]. Thus, the interaction between PEDF
and VEGFR-1 or VEGFR-2 represents a potential
mechanism for the inhibition of angiogenesis.
Hutchings et al. [14] have raised the possibility
that PEDF may operate as a significant
endogenous vasoactive substance, because
PEDF exhibits synergistic action with VEGF
in co-culture with endothelial cells, in conjunction
with increased activation of the mitogen-activated
protein kinases (MAPKs) [14]. Interestingly, PEDF
has been found to induce the expression of
pro-apoptotic FAS ligand (FASL) by nuclear
factor kappa-light-chain-enhancer of activated
B cells (NF-κB) in endothelial cells, and theregulation of NF-κB by PEDF is PEDF-R-
dependent [94], it is therefore conceivable
that PEDF may exert its anti-angiogenic activities
through PEDF-R in endothelial cells.
Degradative regulation of PEDF occurs under
hypoxic conditions. Hypoxia is a primary
physiological regulator of the angiogenic switch
[95], and as such, low oxygen conditions
downregulate PEDF expression [96]. This
effect is due to the induction of matrix
metalloproteinases (MMPs), which are an
integral part of the extracellular matrix
(ECM) enzymatic arsenal [97], and which
proteolytically degrade PEDF. [97] In the
presence of endogenous angiogenic inhibitors
containing fragments or cryptic domains of
large protein molecules [98–100] such as the
plasminogen kringle domain 1–4 (also known
as angiostatin) and the kringle 5 (K5) domain,
however, PEDF expression is upregulated, and
angiogenesis is hampered [23, 96]. Collectively,
these data support the notion that PEDF is a
powerful anti-angiogenic factor that negates
VEGF activity and prevents tumor growth
beyond certain size.
(ii) Proliferation and invasion
The ability of tumor cells to proliferate and
invade healthy tissues is a fundamental
characteristic of cancer. Cell proliferation
results from the increase in cell numbers
following cell division. PEDF is a negative
regulator of cell proliferation. This protein
inhibits the proliferation of various endothelial
cells maintained in culture with fetal growth
factors [14]. Likewise, exogenous PEDF
delivered to cultures of endometrial cancer cells
resulted in reduced cell proliferation [101]. In
vivo, when B16-LS9 melanoma cells that had
been engineered to overexpress PEDF were
injected into the eye of C57BL/6 mice, the
growth of the primary tumor was inhibited, and
the number of metastases to the liver was
decreased, confirming the anti-proliferative role
of PEDF in these cells [102]. Konson et al. [103]
showed that a triple phosphomimetic-altered
PEDF is more efficient than wild-type PEDF in
blocking neovascularization and tumor growth
in vivo, and that this altered protein suppresses
cultured endothelial cell proliferation much
more effectively than wild-type PEDF. These
findings are consistent with the role of PEDF as
an inhibitor of cell proliferation. The exact
mechanism by which PEDF reduces cell
proliferation is still not well understood, but
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of PEDF glycosylation, at least in endothelial
cells. Consistent with this premise, Duh et al.
[104] reported that secreted human recombinant
PEDF (rPEDF) from human embryonic kidney
cells has two species that vary in their
carbohydrate composition at the N-glycosylation
site, as well as in their efficacy of suppressing
VEGF-induced proliferation of microvascular
endothelial cells. Additional experiments,
however, are required to ascertain the exact
role of PEDF glycosylation in the mechanism
of cell proliferation associated with tumor
progression.
When tumor cells and their progeny
proliferate in an uncontrolled manner, they
begin to disperse to other areas of the host
(invasion) [105]. The role of PEDF in cell
invasion has been highlighted by the finding
that PEDF knockdown in poorly aggressive
melanoma cell lines leads to increased invasion
[106]. Similarly, PEDF interference significantly
increased the migratory and invasive capability
of normal melanocytes and enhanced their
proliferative potential [106]. Conversely,
exogenous PEDF delivered into endometrial
cancer cells slowed their invasiveness [101].
PEDF attenuates cell invasion by disabling
MMPs, which are key players in the events
that underlie tumor cell invasion [107]. MMPs
cleave cell surface receptors and degrade ECM
proteins to induce invasion [108]. For example,
membrane type-1 (MT1)-MMP facilitates the
breakdown of the ECM to allow for aberrant
tumor growth, and PEDF functions by
preventing MT1-MMP distribution to the
plasma membrane. The PEDF-dependent
inhibition of MT1-MMP transport to the cell
surface is mediated by a shift in the rat
sarcoma homolog gene family member A
(RhoA) and RAS-related C3 botulinum toxin
substrate 1 (Rac1) balance [109]. RhoA and
Rac1 play cardinal roles in cytoskeletal
dynamics, cell movement, and various other
common cellular functions [110]. Besides
MMPs, PEDF modifies the expression of a
number of genes that have been attributed
in other studies to the malignant progression
of human melanoma. Such genes include
members of the SOX transcription factor
family and genes that belong to the Notch
(NOTCH2NL and JAG1) [111] or Wnt
(DKK1, FZD1, and LEF1) [112, 113] pathways.
Taken together, these studies validate the centralrole of PEDF in the prevention of tumor
proliferation and invasion via various mechanisms,
which are not completely understood and thus
warrant further investigation.
(vi) Metastasis
Metastasis is one of the most significant
problems associated with mortality in cancer
patients [114, 115]. Metastasis occurs when
cancer cells separate from the primary tumor
mass and move to enter blood vessels. These
traveling cells survive within the circulation
by attaching to the endothelium of distant
organs, entering the endothelial barrier, and
establishing new tumor colonies, which are
the primary cause of death. PEDF is a potent
anti-metastatic protein that is lost in highly
aggressive metastatic melanoma [106]. One
good example is the orthotopic model, which
was developed by Dass et al. [116]. The model
demonstrates that PEDF has the greatest
impact on metastases in mice injected with
osteosarcoma lines, with a 70 % reduction in
the development of pulmonary metastases
and a 40 % decrease in primary tumor size
versus untreated controls [116]. In addition,
the expression of PEDF is inversely related to
the metastatic potential and tumor grade of
prostate adenocarcinoma [17], pancreatic
adenocarcinoma [20], glioblastoma [25],
hepatocellular carcinoma, and Wilm’s tumors
[65]. The exact mechanism of action of PEDF
on metastatic cancers is yet to be fully elucidated,
although several reports shed some light on the
numerous and complex signaling activities
employed by PEDF to halt metastasis [23, 117].
For example, the VEGF/PEDF ratio has been
proposed as an angiogenic switch in uveal
melanoma metastasis [23]. Other studies
identified MMPs as key players in the events
that trigger tumor dissemination [118, 119].
For instance, in human chondrosarcoma cell
lines that overexpress PEDF, MMP-14 levels
were markedly low, and reduced trafficking of
membrane-bound MMP-14 to the cell surface
was observed, leading to decreased metastasis
compared to matched controls [119]. Similar to
invasion, this factor attenuates MT1-MMP
function by preventing its distribution to the
plasma membrane through RhoA inhibition
and Rac1 activation [109]. In vivo, knockdown of
Rac1 or overexpression of MT1-MMP was
sufficient to reverse the inhibitory effect of
PEDF on extravasation [109]. Reflecting the
complexity of the phenotype that results
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that several molecules interact with PEDF to
attenuate tumor cell dissemination in various
cancer types. As discussed in the next section,
other biological processes, such as cell death and
cell differentiation, are altered by PEDF
overexpression as well, causing inhibition of
tumor progression.A. Biological processes promoted by PEDF
(i) Apoptosis
The assessment of anti-tumor effects of PEDF
has uncovered apoptosis (physiological cell
death) as a major anti-carcinogenic biological
benefit of this factor. One of the fundamental
mechanisms underlying the anti-angiogenesis
activity of PEDF is its ability to selectively
stimulate endothelial cell apoptosis in actively
remodeling vessels [120, 121] consistent with
the potency of PEDF as an anti-tumorigenic
factor. In vitro, Guan et al. [16] observed
that the overexpression of PEDF in prostate
carcinoma cells was paralleled with elevated
apoptosis in those cells compared to control
cells. In vivo, PEDF exerts growth-suppressive
and pro-apoptotic effects in lung cancer
xenografts [122]. Apoptotic cells were also
markedly increased in tumors derived from
PEDF-overexpressing malignant melanoma
cells, compared with control vector-transfected
tumor cells [21]. Interestingly, when Konson
et al. [123] compared the rate of apoptosis in
PEDF-treated human breast adenocarcinoma
(MDA-MB-231), human colon carcinoma
(HCT116), and glioma (U87-MG) cell lines to
that of PEDF-treated bovine aortic endothelial
cells (BAEC) and human umbilical vein
endothelial cells (HUVEC), they found that
the apoptosis-inducing efficacy of PEDF in
culture was stronger for endothelial cells,
compared to tumor cells. Alternatively, cancer
cells may be more resistant to PEDF action due
to the higher basal activity of their survival
pathways [123].
PEDF stimulates apoptosis of endothelial and
tumor cells through several pathways (Fig. 2).
The extrinsic pathway, which is a cell surface
death receptor-mediated pathway in which FAS
is the most well-known player, and the intrinsic
pathway, which is otherwise identified as the
mitochondrial pathway because of a rise in
mitochondrial permeability, are the best known.
These two pathways have been extensively
described (reviews [124–126]:). Therefore, ourfocus here will be on the interactions of these
pathways with PEDF. The role of PEDF in
apoptosis of endothelial cells via the FAS/FASL
pathway has been demonstrated in elegant
experiments by Volpert et al. [120]. These
experiments revealed that the expression of
pro-apoptotic FAS receptor is low in quiescent
endothelial cells and blood vessels, but is
upregulated by angiogenic factors, such as
VEGF, resulting in sensitization of the stimulated
cells to apoptosis by PEDF-generated
pro-apoptotic FASL. This paradigm of
cooperation between pro- and anti-angiogenic
factors in the prevention of angiogenesis
offers one possible explanation for the ability
of PEDF to choose remodeling capillaries for
destruction; however, the anti-angiogenic
properties of PEDF are still evident when
mice that are deficient for either FAS or
FASL are treated with PEDF [127], implying
that PEDF can also act independently of the
FAS pathway to suppress angiogenesis. In
tumors, PEDF stimulates apoptosis predominantly
via the FASL/FAS pathway [122]; however, PEDF
also utilizes the BCL2 family of proteins, which
are part of the intrinsic pathway, for the induction
of apoptosis. Zhang et al. [91] demonstrated that
pro-apoptotic BAX protein was upregulated, and
anti-apoptotic BCL2 was downregulated by PEDF
in apoptotic glioma cell lines. Whereas these
findings clearly validate a role for PEDF in
the intrinsic pathway, whether PEDF utilizes
any upstream regulators for BAX and BCL2
remains unclear. In fact, a pathway that
incorporates both PEDF and the tumor
suppressor p53, and includes BAX and other
anti-apoptotic BCL2 family proteins has been
described by Ho et al. [128]. These investigators
specifically showed that when PEDF sequentially
induced peroxisome proliferator-activated
receptor gamma (PPARγ) and p53 expression
in endothelial cells, a significant number of
apoptotic cells were observed. The induction
of p53 by PEDF, however, was abolished in
the presence of PPARγ inhibitors. Furthermore,
PEDF-mediated endothelial cell apoptosis was
significantly reduced by p53 siRNA [128]. This
implies that both proteins are pivotal regulators
of PEDF-mediated apoptotic cell death.
Stimulation of p53 can increase the pro-apoptotic
protein p53 upregulated modulator of apoptosis
(PUMA), inducing this protein to initiate the
intrinsic pathway to apoptosis. The overexpression
of PUMA leads to the upregulation of BAX,
Cell death 
      by apoptosis
FAS
FASL




















Fig. 2 Different apoptotic pathways are modulated by PEDF. 1. PEDF contributes to apoptosis in endothelial cells via the extrinsic FAS/FASL
pathway [120] 2. PEDF can sequentially induce the expression of PPARγ and p53 in endothelial cells. Stimulated p53 increases pro-apoptotic
PUMA, inducing this protein to initiate the intrinsic pathway to apoptosis [130] 3. Also, PEDF mediates endothelial cell apoptosis through JNK
activation, leading to cellular FLICE-like inhibitory protein (c-FLIP) blockade, which propels cells into a pro-apoptotic state [130]. 4. PEDF can
utilize the BCL2 family of proteins from the intrinsic pathway to stimulate apoptosis in tumors. Notably, activated caspase-8 stimulates apoptosis via two
parallel cascades: it either directly cleaves and activates caspase-3, or it can cleave BID, a pro-apoptotic BCL2 family protein. tBID activation of BAX results in
oligomerization of BAX on the cell membrane [146]. Anti-apoptotic BCL2 protein inhibits BAX oligomerization by sequestering tBID. The ratio of BAX/BCL2
may be more important than either promoters alone in determining apoptosis [147]. (→) means protein activation, and (—) means protein inhibition
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and then translocates to the mitochondria
with subsequent release of cytochrome c
[129], resulting in the activation of caspases,
and ultimately in the induction of apoptosis.
In addition, PEDF is engaged in the pathway
involving c-Jun NH2-terminal kinase (JNK), a
member of the MAPK family implicated in a
range of biological processes associated with
tumorigenesis [103]. It has been suggested that
PEDF mediates endothelial cell apoptosis
through JNK activation, leading to cellular
FLICE-like inhibitory protein (c-FLIP) blockade,
which propels cells into a pro-apoptotic state[130] (Fig. 2). The cFLIP protein is an intracellular
inhibitor of caspase-8 activation that effectively
prevents death signaling mediated by all known
death receptors, including FAS, tumor necrosis
factor receptor (TNF-R), and TNF-related
apoptosis-inducing ligand receptors (TRAIL-Rs)
[131]. PEDF also stimulates other well-known
signaling molecules that contribute to cell
apoptosis. One such molecule is NF-κB [132],
which is stimulated by PEDF perhaps via the
induction of FASL, a gene that contains NF-κB
binding sites in its promoter region [133–137].
Collectively, these results underscore the idea
that in both endothelial and tumor cells, PEDF
Belkacemi and Zhang Journal of Experimental & Clinical Cancer Research  (2016) 35:4 Page 9 of 14acts on anti- and pro-apoptotic proteins from
various regulatory mechanisms to promote
apoptosis.
(ii) Differentiation
PEDF stimulation of retinoblastoma cell
differentiation provided the first clue about
PEDF-mediated reduction of harmful tumor
phenotypes [37, 132, 138]. In these tumor
cells, PEDF supports neurite development in
concert with elevation of neuronal marker
expression. Since then, Schwann cells, as well
as other brain cells that naturally secrete
PEDF, have been shown to cause neuroblastoma
cell differentiation to yield a less malignant
phenotype [139]. Remarkably, when Crawford
et al. [139] injected rPEDF-expressing cells into
neuroblastoma tumors in vivo, a pale region
corresponding to confluent areas of spindle-
shaped cells, which were characterized by bland
nuclei with abundant cytoplasm, were observed.
These spindled-shaped cells were relatively
different from the more primitive neuroblasts
observed within the tumor distant from the
injection site, whereas the control cells were
formed of undifferentiated neuroblast cells.
These investigators also found that even
treatment with lower PEDF levels induces
discrete areas of tumor cell differentiation.
The molecular mechanisms by which PEDF
mediates tumor cell differentiation to a less
malignant phenotype and protects normal
neuronal cells likely involve a very complex
system of regulation because the PEDF gene,
which harbors a typical signal-peptide
sequence, initiator methionine codon, and
polyadenylation signal, and fits the size of the
other members of the serpin superfamily
(e.g., a1pha 1 anti-trypsin), is not homologous at
the putative serpin reactive center [37]. This
difference implies that PEDF may influence
neuronal differentiation by a mechanism
other than the common inhibition of serine
protease activity. In other organs, such as the
prostate, Filleur et al. [15] and Smith et al.
[140] reported that PEDF contributes to
prostate neuroendocrine differentiation via a
feed-forward mechanism. The induction of
neuroendocrine differentiation, however, may
not be advantageous for patients with prostate
cancer because PEDF expression is negatively
regulated by testosterone [12], and high PEDF
levels due to androgen ablation in cancer
may cause expansion of the neuroendocrine
component and influence both prostatedevelopment and prostate cancer progression
[140]. Thus, the PEDF mediated neuroendocrine
effect on cell differentiation warrants further
investigation in order to gain a better understanding
of the potential of PEDF use for the treatment of
hormone-refractory diseases. Collectively, these
findings suggest that PEDF has the ability to
arrest tumor cell growth and induce differentiation
to a less malignant phenotype while, perhaps
simultaneously, protecting normal cells. Clearly,
such a role requires a complex system of
regulation, which may not always be compatible
with the anti-cancer features of PEDF.Chemotherapeutic potential of PEDF
As an endogenous anti-tumor agent, PEDF has attracted
wide attention. Immunohistochemical analyzes of PEDF
expression in a variety of human tumor specimens and
healthy tissues indicated that upregulated levels of PEDF
expression were associated with a favorable prognosis,
while decreased levels of PEDF were suggestive of a
poorer prognosis [141]. Additionally, tissue microarray
of matched primary and recurrent breast tumors after
treatment with endocrine drug revealed that patients
who had progressive disease, on average 93 months after
endocrine therapy, had markedly lower levels of PEDF
than those who showed a complete therapeutic response
[141]. These findings has led to ongoing efforts focusing
on the use of exogenous PEDF for cancer treatment.
Two main approaches are considered for testing PEDF
as a therapeutic agent. In the gene therapy route, PEDF
was administered as an expressible form in a viral vector,
and had demonstrated, as a proof of principle, that this
form of therapy was effective [69, 142, 143]. Another
route consisted of systemic administration of naked
PEDF (free, unmodified) to tumors, which resulted in
tumor regression caused by the discriminating effect of
the protein on tumors and associated vasculature [65]. It
is believed that with such drug delivery systems, en-
hanced drug pharmacokinetics and pharmacodynamics
will be realized. However, such effort has met with
limited success because of the necessity of continuous
delivery of PEDF gene to sustain its expression in tumors.
Moreover, as PEDF is expressed in healthy organs [144],
the constant injection of this protein, with time, may affect
not only the tumor but also the normal organ functions.
A quite novel approach would consist of boosting
PEDF expression via specific platinum-based chemo-
therapeutic phosphaplatin drugs. Phosphaplatins such
as platinum[II] and platinum[IV] complexes (Fig. 3)
that contain a pyrophosphate moiety exhibit excellent
anti-tumor activities in a variety of cancers [145]. A
leading compound in this class, RRD2 has recently been








Fig. 3 Structure of phosphaplatin compounds. (a) (1,2-
cyclohexanediamine)-(dihydrogen pyrophosphato)-platinum(II),
abbreviated as RRD2. (b) (1,2-cyclohexanediamine)-trans-dihydroxo
(dihydrogen pyrophosphato)-platinum(IV), abbreviated as RRD4
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a phase I clinical trial (ClinicalTrials.gov Identifier:
NCT02266745). The RRD2 significantly stimulates
PEDF expression, and inhibits angiogenesis and cell
migration of HUVECs (RN Bose patent: WO 2014130776
A1). Furthermore, these drugs stimulate PEDF expression
in various tumor cells, including ovarian cells (RN Bose
patent: WO 2014130776 A1). Current effort is devoted to
developing drug delivery systems, such as controlled re-
lease nanoparticles that can potentially be used to deliver
the drug to tumor tissues.
Conclusion
Because PEDF secreted protein affects multiple physio-
logical functions, it is an important determinant of op-
timal development, and ultimately, of lifelong health.
PEDF has been established as an anti-cancer agent, utiliz-
ing several mechanisms for tumor inhibition. Although
the diversity of PEDF activities may seem complex, these
functions are consistent with its pleiotropic activities
impacting both normal and malignant cells. Some of the
molecular mechanisms of PEDF’s multifunctionality could
be explained by responses to interactions with distinct cell
surface receptors. Current investigations will undoubtedly
clarify the details of PEDF signaling cascades and their
biological importance. The importance of PEDF protein
lies in its ability to inhibit tumor growth in several ways
via anti-angiogenesis, anti-metastasis, induction of tumor
cell differentiation and apoptosis. The distinctiveness of
PEDF-mediated anti-angiogenesis stems from its ability to
target only new vessel growth; however, this factor also is
quite stable and nontoxic when injected systemically. Fur-
thermore, the expression of PEDF can be induced by the
nontoxic phosphaplatin drugs. With the completion of
further studies, including those performed in our labora-
tory, demonstrating the anti-tumor effects of PEDF on dif-
ferent cancer types, the role of PEDF as a potential
therapeutic agent is undeniably promising. As relatively
little is known about the overall physiologic role of PEDF
in the human body, further investigations are warranted
prior to clinical studies of PEDF in cancer treatment.Consent for publication
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